MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis
Autor: | Torsten Matthias, Sandra Neidhöfer, Sandra Reuter, Aaron Lerner |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
0301 basic medicine MMP3 medicine.medical_specialty Disease outcome Arthritis Rheumatoid Disease activity 03 medical and health sciences 0302 clinical medicine Rheumatology Internal medicine medicine Humans 030203 arthritis & rheumatology Joint destruction business.industry Bone Injury Middle Aged medicine.disease Therapeutic modalities Treatment Outcome 030104 developmental biology Rheumatoid arthritis Radiological weapon Female Matrix Metalloproteinase 3 business Biomarkers |
Zdroj: | Best Practice & Research Clinical Rheumatology. 32:550-562 |
ISSN: | 1521-6942 |
DOI: | 10.1016/j.berh.2019.01.006 |
Popis: | Matrix metalloproteinase-3 or MMP3 also known as stromelysin-1 is an enzyme that is actively involved in joint destruction in rheumatoid arthritis (RA) patients. Screening the last three decades, it appears that serum levels of MMP3 reflect positively RA disease activity, joint and bone injury, and radiological erosion and predict disease outcome and drug responsiveness as summarized in several publications reporting outcomes on more than 8000 patients with RA. MMP-3 monitoring should be embedded in the routine assessment and accompany therapeutic modalities, in personalized medical RA management. |
Databáze: | OpenAIRE |
Externí odkaz: |